Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan.

By J. Jonker, J. Smit, R. F. Brinkhuis, M. Maliepaard, Jos H. Beijnen, Jan H. M. Schellens, A. Schinkel. Journal of the National Cancer Institute, 2000

682 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/84528eea3fa0ba42da79a32ed8f0f6f9bebc0a39

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. Michael M. Gottesman
2. Jan H. M. Schellens
3. C. Klaassen
4. Lauren M. Aleksunes

In Oncology

1. Michael M. Gottesman
2. S. Bates
3. C. Klaassen
4. T. Fojo
5. Lauren M. Aleksunes

Citations in the corpus

• Multidrug resistance in cancer: role of ATP–dependent transporters (2002, background): “MRP family members and the half-transporter ABCG2 are also localized in placent”
• Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2) (2003, background): “Evidence for this hypothesis was provided by Jonker et al. (2000), who demonstrated that in pregnant, Pgp-deficient mice, fetal penetration of topotecan is increased at least twofold by the BCRP inhibitor GF120918.”
• Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. (2001, methodology): “administered BCRP substrate topotecan in the fetus (29).”
• Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. (2002, background): “substrate drugs (12, 13): in the placenta, where it reduces”
• Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. (2006, background): “In pregnant, Mdr1-deficient mice, when topotecan was coadministered with the inhibitor GF120918, the fetal penetration of topotecan was significantly higher than without this inhibitor (163).”
• Xenobiotic, Bile Acid, and Cholesterol Transporters: Function and Regulation (2010, background): “This was first documented after topotecan accumulated in Bcrp-null fetuses to a greater extent than in wild-type fetuses (Jonker et al., 2000).”